Remdesivir (Veklury®)

Covered: Veklury (remdesivir) is authorized for a single 3‑day, weight‑based course to treat mild‑to‑moderate COVID‑19 in adults and pediatric patients ≥28 days old and ≥3 kg who are at high risk for progression to severe disease; patients <28 days, <3 kg, without a positive SARS‑CoV‑2 test, not at high risk, or with other COVID‑19 severity are excluded. Key requirements: documentation of a positive SARS‑CoV‑2 test, age and weight, evidence of high‑risk status, and adherence to specified dosing (≥40 kg: 200 mg Day 1 then 100 mg Days 2–3; 3 kg–<40 kg: 5 mg/kg Day 1 then 2.5 mg/kg Days 2–3) for one 3‑day treatment course.

"Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (28 days of age and older and weighing at least 3 kg) who has mild-to-moderate COVID-1..."

Sign up to see full coverage criteria, indications, and limitations.